Headquartered in Melville, NY, Henry Schein, Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 32 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #3 (Hold) but that could change following its fourth quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at 97 cents per share. Henry Schein’s adjusted earnings per share remains in line with the estimate.
Revenues: Henry Schein posted net sales of $3.32 billion, ahead of the Zacks Consensus Estimate for revenues of $3.30 billion.
Key Stats: Revenues in the fourth quarter derived from Henry Schein’s Dental segment grew 8.2% year over year to $1.7 billion, while Animal Health segment recorded sales of $889.8 million, up 6.2% compared with the prior-year quarter. Revenues from Medical segment increased 2.6% year over year to $636.9 million, while sales from Technology and Value-added services segment grew 2.1% to $114.6 million.
Major Factors: Per management, its four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions. The company has raised its 2018 EPS guidance to a new range of $4.03 to $4.14, as compared to the earlier-provided band of $3.85 to $3.96
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Headquartered in Melville, NY, Henry Schein, Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 32 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #3 (Hold) but that could change following its fourth quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at 97 cents per share. Henry Schein’s adjusted earnings per share remains in line with the estimate.
Revenues: Henry Schein posted net sales of $3.32 billion, ahead of the Zacks Consensus Estimate for revenues of $3.30 billion.
Key Stats: Revenues in the fourth quarter derived from Henry Schein’s Dental segment grew 8.2% year over year to $1.7 billion, while Animal Health segment recorded sales of $889.8 million, up 6.2% compared with the prior-year quarter. Revenues from Medical segment increased 2.6% year over year to $636.9 million, while sales from Technology and Value-added services segment grew 2.1% to $114.6 million.
Major Factors: Per management, its four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions. The company has raised its 2018 EPS guidance to a new range of $4.03 to $4.14, as compared to the earlier-provided band of $3.85 to $3.96
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on HSIC - FREE